Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 15, Issue 9, Pages 1116-1121Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2009.05.019
Keywords
Infliximab; Steroid-refractory; Acute graft-versus-host disease
Categories
Funding
- National Cancer Center [3 P30-CA7692, 5 K12-CA087989]
- National Center for Research Resources [K30-RR022270]
Ask authors/readers for more resources
Infliximab has demonstrated activity in the treatment of steroid-refractory acute graft-versus-host disease (aGVHD). We aimed to confirm the effectiveness of infliximab as a salvage therapy for steroid-refractory aGVHD. In a series of 52 patients, 71% of whom had grade III-IV aGVHD, only 15% achieved complete remission (CR) with the use of infliximab alone as salvage therapy. CR of aGVHD differed according to overall aGVHD grade at salvage (grade II, 5/15; grade III, 2/17; grade IV, 1/20; P = .03). Median overall survival (OS) was only 1.7 months (95% confidence interval [CI] = 0.99 to 2.3 months). CR of aGVHD was significantly associated with OS, with a hazard ratio of 8.4 for death in those without CR (95% CI = 3.6 to 19.6; P < .0001). This series demonstrates the limited activity of infliximab in patients with high-grade aGVHD. Further work is needed to identify effective therapy for aGVHD. Biol Blood Marrow; Transplant 15: 1116-1121 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available